The first patent for Exforge (amlodipine and valsartan) has expired, but no generic versions are available yet. Although it's unclear why no generic versions have been introduced, it's likely that the drug is still protected by another patent that has not yet expired.
Exforge® (amlodipine and valsartan) is a prescription medication used to treat high blood pressure (known medically as hypertension).
Currently, Exforge is made by Novartis Pharmaceuticals. It is currently under the protection of a patent that prevents any generic Exforge from being manufactured in the United States.
The first patent for Exforge expired in September 2012. However, no generic versions are yet available. This strongly suggests that one or more later-expiring patents are still protecting the drug from generic competition.
The next Exforge patent is set to expire in December 2017. This is the earliest predictable date that a generic version could become available. However, other circumstances could come up to extend the exclusivity period. This could include such things as other patents for specific Exforge uses or lawsuits.
Once the drug goes off-patent, several companies may begin manufacturing a generic Exforge drug.
Exforge contains two medications: amlodipine (Norvasc®) and valsartan (Diovan®). Depending on your insurance plan, it might be less expensive (although less convenient) to take the two medications separately. However, insurance plans vary widely, so check with your insurance provider to see if this option might be less expensive.